BE2019C523I2 - - Google Patents

Download PDF

Info

Publication number
BE2019C523I2
BE2019C523I2 BE2019C523C BE2019C523C BE2019C523I2 BE 2019C523 I2 BE2019C523 I2 BE 2019C523I2 BE 2019C523 C BE2019C523 C BE 2019C523C BE 2019C523 C BE2019C523 C BE 2019C523C BE 2019C523 I2 BE2019C523 I2 BE 2019C523I2
Authority
BE
Belgium
Application number
BE2019C523C
Other languages
Dutch (nl)
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36337298&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2019C523(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of BE2019C523I2 publication Critical patent/BE2019C523I2/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
BE2019C523C 2004-11-12 2019-05-07 BE2019C523I2 (cs)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62727704P 2004-11-12 2004-11-12
PCT/US2005/041205 WO2006053299A2 (en) 2004-11-12 2005-11-14 Site-directed modification of fviii

Publications (1)

Publication Number Publication Date
BE2019C523I2 true BE2019C523I2 (cs) 2025-02-10

Family

ID=36337298

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2019C523C BE2019C523I2 (cs) 2004-11-12 2019-05-07

Country Status (32)

Country Link
US (4) US7632921B2 (cs)
EP (9) EP2772500B1 (cs)
JP (5) JP2008524117A (cs)
KR (7) KR101904630B1 (cs)
CN (6) CN105148287B (cs)
AU (1) AU2005304622B2 (cs)
BE (1) BE2019C523I2 (cs)
BR (2) BR122016022033B8 (cs)
CA (1) CA2586379C (cs)
CY (3) CY1119292T1 (cs)
DK (3) DK2363414T3 (cs)
ES (4) ES2930143T3 (cs)
FR (1) FR19C1031I2 (cs)
HN (1) HN2007015683A (cs)
HR (2) HRP20180481B1 (cs)
HU (5) HUE033776T2 (cs)
IL (3) IL182903A (cs)
LT (5) LT2363414T (cs)
LU (1) LUC00118I2 (cs)
MA (1) MA29663B1 (cs)
MX (3) MX350293B (cs)
NL (1) NL300989I2 (cs)
NO (3) NO20210454A1 (cs)
NZ (1) NZ555032A (cs)
PH (2) PH12014500352B1 (cs)
PL (3) PL2363414T3 (cs)
PT (4) PT3130601T (cs)
RU (1) RU2423380C2 (cs)
SI (4) SI2363414T1 (cs)
UA (1) UA95225C2 (cs)
WO (1) WO2006053299A2 (cs)
ZA (1) ZA200703696B (cs)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2522345A1 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
ES2390082T5 (es) * 2004-06-30 2018-01-19 Nektar Therapeutics Conjugados de resto de Factor IX y polímeros
EP1771066A2 (en) 2004-07-13 2007-04-11 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1
US20080176790A1 (en) 2004-10-29 2008-07-24 Defrees Shawn Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf)
HRP20180481B1 (hr) 2004-11-12 2022-02-18 Bayer Healthcare Llc Ciljana modifikacija faktora viii
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
WO2006121569A2 (en) 2005-04-08 2006-11-16 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
WO2006134173A2 (en) 2005-06-17 2006-12-21 Novo Nordisk Health Care Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
EP2213733A3 (en) * 2006-05-24 2010-12-29 Novo Nordisk Health Care AG Factor IX analogues having prolonged in vivo half life
CN101516388B (zh) 2006-07-21 2012-10-31 诺和诺德公司 通过o-联糖基化序列的肽的糖基化
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
ES2655639T3 (es) 2006-12-15 2018-02-21 Baxalta GmbH Conjugado de factor VIIa - ácido (poli)siálico que tiene una semivida in vivo prolongada
PT2144923E (pt) 2007-04-03 2013-05-15 Biogenerix Ag Métodos de tratamento com g-csf glicopeguilado
EP2170919B8 (en) 2007-06-12 2016-01-20 ratiopharm GmbH Improved process for the production of nucleotide sugars
JP2011503101A (ja) * 2007-11-09 2011-01-27 バクスター・インターナショナル・インコーポレイテッド 修飾された組換え第ｖｉｉｉ因子およびフォンウィルブランド因子ならびにその使用方法
RU2573587C2 (ru) 2008-02-27 2016-01-20 Ново Нордиск А/С Конъюгированные молекулы фактора viii
WO2009140598A1 (en) 2008-05-16 2009-11-19 Bayer Healthcare Llc Targeted coagulation factors and method of using the same
EP2297330A4 (en) * 2008-06-04 2012-03-14 Bayer Healthcare Llc FVII MUTINES FOR THE TREATMENT OF MORBUS WILLEBRAND
ES2654336T3 (es) 2008-06-24 2018-02-13 Csl Behring Gmbh Factor VIII, factor de von Willebrand o sus complejos con semivida in vivo prolongada
WO2010019263A2 (en) * 2008-08-15 2010-02-18 Genzyme Corporation Soluble flt constructs for treating cancers
KR101929641B1 (ko) * 2008-10-17 2018-12-14 박스알타 인코퍼레이티드 낮은 수준의 수용성 중합체를 포함하는 개질된 혈액 인자
EP2352515A4 (en) * 2008-11-03 2012-04-25 Bayer Healthcare Llc METHOD FOR TREATING HEMOPHILIA
JP2012510060A (ja) * 2008-11-24 2012-04-26 バイエル・ヘルスケア・エルエルシー シリカをベースとする活性化部分トロンボプラスチン時間アッセイにおけるｐｅｇ化血液凝固因子の活性の測定方法
WO2010083536A1 (en) * 2009-01-19 2010-07-22 Bayer Healthcare Llc Protein conjugate having an endopeptidase-cleavable bioprotective moiety
US8716448B2 (en) 2009-02-03 2014-05-06 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
CN102348715B (zh) 2009-02-03 2017-12-08 阿穆尼克斯运营公司 延伸重组多肽和包含该延伸重组多肽的组合物
EP2398822B1 (en) * 2009-02-19 2013-01-02 Novo Nordisk A/S Modification of factor viii
PL2408800T3 (pl) * 2009-03-20 2016-11-30 Sposób wytwarzania koniugatu miejscowo-specyficznego, fizjologicznie aktywnego polipeptydu
CA2756197A1 (en) * 2009-03-24 2010-09-30 Bayer Healthcare Llc Factor viii variants and methods of use
TWI537006B (zh) 2009-07-27 2016-06-11 巴克斯歐塔公司 凝血蛋白接合物
RU2533619C2 (ru) 2009-07-27 2014-11-20 Лайпоксен Текнолоджиз Лимитед Гликополисиалирование белков, не являющихся белками свертывания крови
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
EP3093029A1 (en) 2009-07-27 2016-11-16 Baxalta GmbH Blood coagulation protein conjugates
EP4382170A3 (en) 2009-12-06 2024-09-04 Bioverativ Therapeutics Inc. Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
CN105524164A (zh) 2010-02-16 2016-04-27 诺沃—诺迪斯克有限公司 具有降低的vwf结合的因子viii分子
MX2012009674A (es) * 2010-02-21 2012-09-07 Bayer Healthcare Llc Procedimiento de activacion y conjugacion de biomoleculas.
EP3549963B1 (en) 2010-04-15 2022-01-12 Kodiak Sciences Inc. High molecular weight zwitterion-containing polymers
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
GB201007357D0 (en) * 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
EP3508573A1 (en) 2010-07-09 2019-07-10 Bioverativ Therapeutics Inc. Systems for factor viii processing and methods thereof
SG190136A1 (en) * 2010-11-05 2013-07-31 Baxter Int A new variant of antihemophilic factor viii having increased specific activity
WO2012079979A1 (en) * 2010-12-16 2012-06-21 Novo Nordisk A/S Aqueous factor viii solution
CN103269723B (zh) 2010-12-22 2017-04-05 百深有限责任公司 用于偶联水溶性脂肪酸衍生物与蛋白质的材料和方法
EP3412314A1 (en) * 2011-05-27 2018-12-12 Baxalta GmbH Therapeutic proteins conjugated to polysialic acid and methods of preparing same
HRP20190494T1 (hr) 2011-06-10 2019-07-12 Bioverativ Therapeutics Inc. Pro-koagulantski spojevi i postupci njihove uporabe
CA2840552A1 (en) 2011-07-01 2013-01-10 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
EP4169525A1 (en) 2011-07-08 2023-04-26 Bioverativ Therapeutics Inc. Factor viii chimeric and hybrid polypeptides, and methods of use thereof
KR20140070612A (ko) 2011-09-23 2014-06-10 노보 노르디스크 에이/에스 신규 글루카곤 유사체
KR20130049671A (ko) * 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
SG10201606783RA (en) 2012-02-15 2016-10-28 Amunix Operating Inc Factor viii compositions and methods of making and using same
HRP20190454T1 (hr) * 2012-02-15 2019-05-03 Bioverativ Therapeutics Inc. Rekombinantni faktor viii proteini
US9458223B2 (en) 2012-02-15 2016-10-04 Csl Behring Gmbh Von willebrand factor variants having improved factor VIII binding affinity
EP2666782A1 (en) * 2012-05-22 2013-11-27 Imnate Sarl Coagulation factor VIII with reduced immunogenicity.
WO2013185113A1 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Procoagulant compounds
EP2870250B2 (en) 2012-07-06 2022-06-29 Bioverativ Therapeutics Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
HK1213767A1 (zh) 2012-10-18 2016-07-15 Bioverativ Therapeutics Inc. 使用固定劑量凝血因子的方法
EP3943102A1 (en) 2012-10-30 2022-01-26 Bioverativ Therapeutics Inc. Methods of using fviii polypeptide
PT3666283T (pt) 2013-03-15 2022-09-13 Bioverativ Therapeutics Inc Formulações de polipéptido de fator viii
BR112015022730A2 (pt) * 2013-03-15 2017-10-31 Bayer Healthcare Llc formulações de rfviii, método para conjugação covalente de rfviii com um polímero biocompatível e uso de rfviii no preparo de formulação de rfviii para tratamento de hemofilia a
SG10201913874TA (en) 2013-03-15 2020-03-30 Biogen Ma Inc Factor ix polypeptide formulations
JP6594856B2 (ja) 2013-04-18 2019-10-23 ノヴォ ノルディスク アー／エス 医療用の安定な遷延性ｇｌｐ−１／グルカゴン受容体コアゴニスト
ES2657291T3 (es) 2013-04-22 2018-03-02 Csl Ltd. Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
TW201519900A (zh) * 2013-04-28 2015-06-01 Bayer Healthcare Llc 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法
EP3033098B1 (en) 2013-08-14 2022-06-22 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
TWI667255B (zh) 2013-08-14 2019-08-01 美商生物化學醫療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
PL3041513T3 (pl) 2013-09-08 2021-01-25 Kodiak Sciences Inc. Obojnaczojonowe polimerowe koniugaty czynnika viii
JP2016534083A (ja) * 2013-10-22 2016-11-04 デベヴェ・テクノロジーズ 血液因子に対する寛容を誘導することによって血友病を処置する方法
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
RU2546297C1 (ru) * 2013-11-19 2015-04-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук Средство, улучшающее реологические свойства крови
ES2967617T3 (es) 2013-12-06 2024-05-03 Bioverativ Therapeutics Inc Herramientas de farmacocinética poblacional y sus usos
DK3097118T3 (en) * 2014-01-20 2018-11-05 Octapharma Ag PROCEDURE FOR MANUFACTURING FACTOR VIII WITH AN IMPROVED FVIII: C / FVIII: AG RELATIONSHIP
WO2015120056A1 (en) 2014-02-04 2015-08-13 Biogen Ma Inc. Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
EP3114138B1 (en) 2014-03-05 2021-11-17 Pfizer Inc. Improved muteins of clotting factor viii
MX387269B (es) 2014-03-24 2025-03-18 Bioverativ Therapeutics Inc Formulaciones de factor ix liofilizadas.
WO2015154090A1 (en) * 2014-04-04 2015-10-08 Bloodworks Routine laboratory and point-of-care (poc) testing for hemostasis
AU2015243961A1 (en) 2014-04-10 2016-10-27 Bayer Healthcare Llc Compounded media powder formulation and method of preparation of liquid medium for cell culture
WO2015185640A1 (en) 2014-06-04 2015-12-10 Novo Nordisk A/S Glp-1/glucagon receptor co-agonists for medical use
US10253088B2 (en) 2014-07-02 2019-04-09 CSL Behring Lengnau AG Modified von Willebrand Factor
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
BR112017018468A2 (pt) 2015-03-06 2018-04-17 Csl Behring Recombinant Facility Ag fator de von willebrand modificado com meia-vida aumentada
AU2016267539B2 (en) 2015-05-22 2019-12-05 CSL Behring Lengnau AG Methods for preparing modified von willebrand factor
US10688157B2 (en) 2015-05-22 2020-06-23 CSL Behring Lengnau AG Truncated von Willebrand factor polypeptides for treating hemophilia
MX2018001497A (es) 2015-08-03 2018-05-15 Bioverativ Therapeutics Inc Proteinas de fusion de factor ix y metodos para producirlas y usarlas.
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
US10806774B2 (en) 2016-01-07 2020-10-20 CSL Behring Lengnau AG Mutated truncated von Willebrand Factor
SG10201912857XA (en) 2016-01-07 2020-02-27 CSL Behring Lengnau AG Mutated von willebrand factor
JP7235511B2 (ja) * 2016-06-24 2023-03-08 モガム・インスティテュート・フォー・バイオメディカル・リサーチ 組換え型一本鎖ｆｖｉｉｉおよびその化学コンジュゲート
KR20190073576A (ko) 2016-11-11 2019-06-26 체에스엘 베링 렝나우 아게 혈액 응고 장애의 치료 또는 예방에서 혈관외 투여를 위한 절단된 폰 빌레브란트 인자 폴리펩타이드
CA3043250A1 (en) 2016-11-11 2018-05-17 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia
US11104718B2 (en) 2016-11-16 2021-08-31 Bayer Healthcare Llc Red blood cell targeted factor VIII and method of using the same
CN110520149A (zh) 2016-12-02 2019-11-29 比奥维拉迪维治疗股份有限公司 诱导对凝血因子的免疫耐受性的方法
CN110520150A (zh) 2016-12-02 2019-11-29 比奥维拉迪维治疗股份有限公司 使用嵌合凝血因子治疗血友病性关节病的方法
CA3051862A1 (en) 2017-01-31 2018-08-09 Bioverativ Therapeutics Inc. Factor ix fusion proteins and methods of making and using same
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
KR20190086269A (ko) * 2018-01-12 2019-07-22 재단법인 목암생명과학연구소 체내 지속형 재조합 당단백질 및 이의 제조방법
PL3793588T3 (pl) 2018-05-18 2025-09-01 Bioverativ Therapeutics Inc. Sposoby leczenia hemofilii a
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021091881A1 (en) * 2019-11-04 2021-05-14 The Trustees Of Columbia University In The City Of New York High concentration cell penetrating caspase inhibitor conjugates compositions and methods thereof
US20220403005A1 (en) * 2019-12-06 2022-12-22 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor viii function

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59172425A (ja) * 1983-03-18 1984-09-29 Nippon Chemiphar Co Ltd 新規な血液凝固因子誘導体およびその製造法ならびにそれを含有する血液凝固促進剤
US7138505B1 (en) 1984-01-12 2006-11-21 Novartis Vaccines And Diagnostics, Inc. Factor VIII:C nucleic acid molecules
US4970300A (en) 1985-02-01 1990-11-13 New York University Modified factor VIII
US5451521A (en) 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
EP0294910B1 (en) 1987-06-12 1996-09-11 Immuno Ag Novel proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them
US5171844A (en) 1987-06-12 1992-12-15 Gist-Brocades N.W. Proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
AU2473388A (en) * 1987-11-16 1989-06-22 Scripps Clinic And Research Foundation Treatment of factor viii inhibitors
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US6037452A (en) 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
CZ290342B6 (cs) 1992-10-02 2002-07-17 Genetics Institute Inc. Kompozice stabilní při skladování, obsahující koagulační faktor VIII a neiontovou povrchově aktivní látku a způsob její výroby
AU6029594A (en) * 1993-01-15 1994-08-15 Enzon, Inc. Factor viii - polymeric conjugates
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
WO1995011987A1 (en) 1993-10-29 1995-05-04 Incyte Pharmaceuticals, Inc. Chimeric proteins including protease nexin-1 variants
IL113010A (en) 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
BE1008491A3 (fr) * 1994-07-14 1996-05-07 Croix Rouge De Belgique Depart Sequence polypeptidique antigenique du facteur viii, fragments et/ou epitopes de celle-ci.
WO1996041813A2 (en) 1994-11-09 1996-12-27 Offord Robin E Functionalized polymers for site-specific attachment
EP0776530A4 (en) * 1995-06-21 1998-06-10 Motorola Inc METHOD AND ANTENNA PRODUCING AN OMNIDIRECTIONAL RADIATION DIAGRAM
WO1997003195A1 (en) 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs with altered protease sites
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
AT403438B (de) 1996-05-24 1998-02-25 Immuno Ag Pharmazeutische präparation mit faktor viii prokoagulationsaktivität und vwf-bindungsaktivität
US6458563B1 (en) * 1996-06-26 2002-10-01 Emory University Modified factor VIII
US6077939A (en) * 1996-08-02 2000-06-20 Ortho-Mcneil Pharmaceutical, Inc. Methods and kits for making polypeptides having a single covalently bound N-terminal water-soluble polymer
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
IL133974A0 (en) 1997-07-14 2001-04-30 Bolder Biotechnology Inc Derivatives of growth hormone and related proteins
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
WO1999020288A1 (en) * 1997-10-17 1999-04-29 Harvest Technologies Corporation Precipitation of growth-factor-enriched fibrinogen concentrate from platelet rich plasma
EP0922446A1 (en) 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Solution-phase site-specific preparation of GRF-PEG conjugates
PT1079805E (pt) 1998-04-27 2005-03-31 Opperbas Holding Bv Composicao farmaceutica compreendendo factor viii e lipossomas neutros
US6759216B1 (en) 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
DK1129186T4 (da) 1998-11-10 2017-02-06 Stichting Sanquin Bloedvoorziening Et faktor VIII-polypeptid med faktor VIII:C-aktivitet
US6136599A (en) 1998-12-10 2000-10-24 Bayer Corporation Human hybrid host cell for mammalian gene expression
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
NZ513077A (en) 1999-01-14 2004-03-26 Bolder Biotechnology Inc Methods for making proteins containing free cysteine residues
EP1183354A2 (en) 1999-05-24 2002-03-06 The American National Red Cross Methods of reducing factor viii clearance and compositions therefor
EP1982732A3 (en) * 2000-02-11 2011-06-08 Bayer HealthCare LLC Factor VII or VIIA-like conjugates
RU2003107100A (ru) 2000-09-19 2004-08-27 Эмори Юниверсити (Us) Модифицированный фактор viii
EP1351986A2 (en) 2001-01-12 2003-10-15 The American National Red Cross Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii
CZ20032454A3 (en) * 2001-03-22 2004-03-17 Novo Nordisk Health Care Ag Coagulation factor vii derivative
WO2002096454A1 (en) 2001-05-31 2002-12-05 D. Collen Research Foundation Vzw Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
WO2002098454A2 (en) 2001-05-31 2002-12-12 D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
DE60234193D1 (de) 2001-06-14 2009-12-10 Scripps Research Inst Stabilisierte faktor viii mit gentechnisch konstruierten disulfidbindungen
AU2002337901B2 (en) 2001-10-05 2008-01-17 Expression Therapeutics Llc Nucleic acid and amino acid sequences encoding high-level expressor factor VIII polypeptides and methods of use
KR20040103970A (ko) 2002-04-18 2004-12-09 메르크 파텐트 게엠베하 변형된 펙터 ⅷ
US8003117B2 (en) 2002-11-20 2011-08-23 Nof Corporation Polyalkylene glycol derivative and modified bio-related substance
JP4412461B2 (ja) 2002-11-20 2010-02-10 日油株式会社 修飾された生体関連物質、その製造方法および中間体
WO2004060965A2 (en) 2002-12-31 2004-07-22 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
ATE399185T1 (de) 2002-12-31 2008-07-15 Nektar Therapeutics Al Corp Maleinsäureamid polymerderivate und ihre biokonjugate
US7910661B2 (en) 2003-01-06 2011-03-22 Nektar Therapeutics Thiol-selective water-soluble polymer derivatives
DK1596887T3 (da) * 2003-02-26 2022-06-20 Nektar Therapeutics Polymer-Faktor VIII-konjugat
US20050176108A1 (en) 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
US20040180054A1 (en) 2003-03-13 2004-09-16 Hanmi Pharm. Co., Ltd. Physiologically active polypeptide conjugate having prolonged in vivo half-life
EP2336162A1 (en) 2003-05-12 2011-06-22 Affymax, Inc. Novel poly (ethylene glycol) modified erythropoietin agonists and uses thereof
EP2644206B1 (en) 2003-05-23 2019-04-03 Nektar Therapeutics PEG derivatives containing two PEG chains
EP1502921A1 (en) 2003-07-29 2005-02-02 ZLB Behring GmbH Recombinant mutated human factor VIII (FVIII) with improved stability
EP1682106A4 (en) 2003-10-30 2008-06-11 Univ Emory MODIFIED FVIII WITH REDUCED IMMUNOGENICITY BY MUTAGENESIS OF A2 AND C2 EPITOPES
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
CA2547569C (en) 2003-12-03 2013-04-16 University Of Rochester Recombinant factor viii having increased specific activity
WO2006027111A1 (en) 2004-09-06 2006-03-16 Zlb Behring Gmbh Modified coagulation factor viii with enhanced stability
HRP20180481B1 (hr) 2004-11-12 2022-02-18 Bayer Healthcare Llc Ciljana modifikacija faktora viii
EP1871801A2 (en) 2005-04-01 2008-01-02 Novo Nordisk Health Care AG Blood coagulation fviii analogues
US7645860B2 (en) * 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
CA2647314A1 (en) * 2006-03-31 2007-11-08 Baxter International Inc. Pegylated factor viii

Also Published As

Publication number Publication date
KR20180110192A (ko) 2018-10-08
CN103214569A (zh) 2013-07-24
KR101654011B1 (ko) 2016-09-05
FR19C1031I1 (cs) 2019-06-28
JP2017101028A (ja) 2017-06-08
BRPI0517795A8 (pt) 2018-12-26
NO20200044A1 (no) 2007-06-27
HRP20070268B1 (hr) 2018-04-20
JP2013067621A (ja) 2013-04-18
IL232540A0 (en) 2014-06-30
EP3243833B1 (en) 2020-06-17
US9364520B2 (en) 2016-06-14
EP1824988B1 (en) 2017-04-19
JP2008524117A (ja) 2008-07-10
NL300989I2 (nl) 2019-11-28
EP1824988A2 (en) 2007-08-29
EP2371856B1 (en) 2022-05-18
WO2006053299A2 (en) 2006-05-18
EP3130601A1 (en) 2017-02-15
CN103102406A (zh) 2013-05-15
EP2371856A3 (en) 2012-03-14
NO20072997L (no) 2007-06-27
KR20160105928A (ko) 2016-09-07
DK2363414T3 (da) 2022-08-08
HUE060016T2 (hu) 2023-01-28
JP6018238B2 (ja) 2016-11-02
KR20070110260A (ko) 2007-11-16
ES2633916T3 (es) 2017-09-26
NO20210454A1 (no) 2007-06-27
SI2363414T1 (sl) 2022-09-30
DK2371856T3 (en) 2022-08-08
KR20120136413A (ko) 2012-12-18
LTC1824988I2 (lt) 2021-02-25
HRP20180481B1 (hr) 2022-02-18
HK1218718A1 (zh) 2017-03-10
ES2930159T3 (es) 2022-12-07
US9096656B2 (en) 2015-08-04
EP3323829B1 (en) 2020-07-15
HK1182121A1 (en) 2013-11-22
CN107082806A (zh) 2017-08-22
EP3130601B1 (en) 2020-07-15
CY1119292T1 (el) 2018-02-14
HN2007015683A (es) 2011-07-11
EP2363414A2 (en) 2011-09-07
SI1824988T1 (sl) 2017-11-30
ES2821832T3 (es) 2021-04-27
LUC00118I1 (cs) 2019-05-13
LUC00118I2 (cs) 2019-12-27
AU2005304622B2 (en) 2012-03-29
PT2363414T (pt) 2022-08-04
EP2363414B1 (en) 2022-05-18
EP3243833A1 (en) 2017-11-15
CN105148287A (zh) 2015-12-16
FR19C1031I2 (fr) 2020-06-05
BRPI0517795B8 (pt) 2021-05-25
MX350293B (es) 2017-09-04
HRP20070268A2 (hr) 2007-09-30
IL234433B (en) 2019-11-28
NO345800B1 (no) 2021-08-09
KR101468345B1 (ko) 2014-12-03
WO2006053299A3 (en) 2006-08-24
MX2007005466A (es) 2007-10-19
LT3130601T (lt) 2020-09-10
LT1824988T (lt) 2017-10-25
RU2423380C2 (ru) 2011-07-10
RU2007121517A (ru) 2008-12-20
CN105753968A (zh) 2016-07-13
CN103102406B (zh) 2015-05-27
IL182903A0 (en) 2007-08-19
EP1824988A4 (en) 2008-12-31
CY2019024I2 (el) 2019-11-27
PH12019501613A1 (en) 2020-09-14
HUE059193T2 (hu) 2022-10-28
PT1824988T (pt) 2017-07-21
UA95225C2 (ru) 2011-07-25
CY2019024I1 (el) 2019-11-27
EP3153181A1 (en) 2017-04-12
PL2363414T3 (pl) 2022-09-05
BRPI0517795A (pt) 2008-10-21
HRP20180481A2 (hr) 2018-06-29
BRPI0517795B1 (pt) 2020-03-31
PL2371856T3 (pl) 2022-08-22
PT3130601T (pt) 2020-10-01
US20160051633A1 (en) 2016-02-25
KR101483917B1 (ko) 2015-01-16
IL182903A (en) 2014-09-30
EP2772500B1 (en) 2019-12-25
KR20130036780A (ko) 2013-04-12
EP2371856A2 (en) 2011-10-05
KR20140091618A (ko) 2014-07-21
LT2371856T (lt) 2022-08-25
CN103214569B (zh) 2016-12-28
HK1117875A1 (en) 2009-01-23
MX392760B (es) 2025-03-24
ES2930143T3 (es) 2022-12-07
HUE033776T2 (en) 2018-01-29
CN105148287B (zh) 2019-07-09
PH12014500352B1 (en) 2019-09-25
CN101124331A (zh) 2008-02-13
NO344606B1 (no) 2020-02-10
US20060115876A1 (en) 2006-06-01
JP2015134780A (ja) 2015-07-27
PT2371856T (pt) 2022-08-12
US7632921B2 (en) 2009-12-15
EP2363414A3 (en) 2012-03-21
HUS1900026I1 (hu) 2022-04-28
JP6109523B2 (ja) 2017-04-05
ZA200703696B (en) 2008-08-27
LT2363414T (lt) 2022-10-25
JP6487895B2 (ja) 2019-03-20
LTPA2019509I1 (lt) 2019-08-26
NL300989I1 (nl) 2019-05-22
KR20140019489A (ko) 2014-02-14
PH12014500352A1 (en) 2015-07-20
CA2586379A1 (en) 2006-05-18
PL1824988T3 (pl) 2018-01-31
AU2005304622A1 (en) 2006-05-18
JP2017105773A (ja) 2017-06-15
NZ555032A (en) 2010-02-26
DK1824988T3 (en) 2017-08-07
US20130274445A1 (en) 2013-10-17
MA29663B1 (fr) 2008-08-01
SI3130601T1 (sl) 2020-11-30
HUE050542T2 (hu) 2020-12-28
US20100081615A1 (en) 2010-04-01
CA2586379C (en) 2012-04-03
JP6559642B2 (ja) 2019-08-14
BR122016022033B1 (pt) 2021-03-02
CY1123384T1 (el) 2021-12-31
KR101243564B1 (ko) 2013-03-27
SI2371856T1 (sl) 2022-09-30
KR101904630B1 (ko) 2018-10-04
IL232540A (en) 2017-08-31
BR122016022033B8 (pt) 2021-05-25
CN101124331B (zh) 2013-04-24
EP2772500A1 (en) 2014-09-03
EP3243834A1 (en) 2017-11-15
EP3323829A1 (en) 2018-05-23

Similar Documents

Publication Publication Date Title
BE2024C508I2 (cs)
BE2022C549I2 (cs)
BE2023C542I2 (cs)
BE2021C001I2 (cs)
BE2020C513I2 (cs)
BE2020C517I2 (cs)
BE2019C540I2 (cs)
BE2019C523I2 (cs)
BE2019C548I2 (cs)
BE2019C506I2 (cs)
BE2018C045I2 (cs)
BE2020C525I2 (cs)
BE2017C063I2 (cs)
BE2017C027I2 (cs)
BE2017C023I2 (cs)
BE2017C002I2 (cs)
BE2016C067I2 (cs)
BE2016C014I2 (cs)
BE2015C041I2 (cs)
BE2015C038I2 (cs)
BE2015C014I2 (cs)
BE2015C015I2 (cs)
BE2015C066I2 (cs)
BE2014C071I2 (cs)
BE2014C064I2 (cs)